ViGenCell Inc is a Korea-based company principally engaged in the development of cell therapy business. The Company is engaged in the development and manufacture of immuno-cancer cell therapy products and immunosuppressive cell therapy products. In addition, the Company is engaged in the provision of vitier platform as an antigen-specific killing t cell treatment, viranger platform as a gammadelta t cell gene therapy and vimedier platform-based technology as a myeloid suppressor cell therapy derived from umbilical cord blood. It is engaged in the research and development of new drugs such as acute myeloid leukemia (AML) and glioblastoma.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
15/07/26	₩5,880.00	+13.29%	246,825
14/07/26	₩5,190.00	-3.71%	256,154
13/07/26	₩5,390.00	-2.36%	507,109
10/07/26	₩5,520.00	-0.36%	172,382
09/07/26	₩5,540.00	-5.14%	356,818

End-of-day quote Korea S.E.

More quotes

Income Statement and Estimates

More financial data

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

End-of-day quote Korea S.E. Other stock markets 15/07/2026			5-day change	1st Jan Change
5,880.00 ^KRW	+13.29%		+0.68%	-39.69%

23/01/25	Gaeun Global Co.,Ltd completed the acquisition of 11.36% stake in ViGenCell Inc. from Boryung Corporation.	CI
18/12/24	Gaeun Global Co.,Ltd agreed to acquire 11.36% stake in ViGenCell Inc. from Boryung Corporation for KRW 7.9 billion.	CI

Market Cap	200B 134M 117M 108M 99.47M 188M 12.91B 192M 1.29B 507M 6.31B 504M 493M 21.75B	P/E 2023	-6.24x	P/E 2024	-3.42x
Enterprise Value	162B 109M 95.33M 87.94M 80.84M 153M 10.49B 156M 1.05B 412M 5.13B 409M 400M 17.67B	EV / Sales 2023	-	EV / Sales 2024	38,429,949x
Free-Float	73.84%	Yield 2023 *	-	Yield 2024	-

23/01/25	Gaeun Global Co.,Ltd completed the acquisition of 11.36% stake in ViGenCell Inc. from Boryung Corporation.	CI
18/12/24	Gaeun Global Co.,Ltd agreed to acquire 11.36% stake in ViGenCell Inc. from Boryung Corporation for KRW 7.9 billion.	CI
18/09/23	ViGenCell Inc.(KOSDAQ:A308080) dropped from S&P Global BMI Index	CI
15/03/23	ViGenCell Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	CI
21/03/22	ViGenCell Inc.(KOSDAQ:A308080) added to S&P Global BMI Index	CI

1 day	+13.29%
1 week	+0.68%
Current month	-5.92%
1 month	-25.38%
3 months	+5.00%
6 months	-34.59%
Current year	-39.69%

ViGenCell Inc. Stock

Stocks

A308080

KR7308080001

Biotechnology & Medical Research

Valuation: ViGenCell Inc.

Chart: ViGenCell Inc.

Latest news : ViGenCell Inc.

Quotes and Performance

Course Extremes

Managers and Directors: ViGenCell Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

1 week	4,950	6,480
1 month	4,950	7,840
Current year	4,700	14,400
1 year	3,070	17,360
3 years	2,305	17,360
5 years	2,305	39,000
10 years	2,305	39,000

Manager	Title	Age	Since
Pyung-suk Ki CEO	Chief Executive Officer	-	-
Tae Gyu Kim CEO	Chief Executive Officer	68	-
Hyun-Jung Son PRN	Corporate Officer/Principal	53	-

Director	Title	Age	Since
Tae Gyu Kim BRD	Director/Board Member	68	-
Kyung-Muk Kim BRD	Director/Board Member	57	-
Hyun-Jung Son BRD	Director/Board Member	53	-

Date	Insider	Type	Main position	Quantity	% Market Cap.
30/04/24	Kyung-Muk Kim	Fiscal year	Director	63,000	0.3287%
30/04/24	Seong-Jong Kim	Fiscal year		35,000	0.1826%
30/04/24	Seong-Jong Kim	Don		40,440	0.2110%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
VIGENCELL INC.	+13.29%	+0.68%	+54.74%	-11.71%	80.91M
WUXI APPTEC CO., LTD.	+3.13%	+13.95%	+64.21%	+94.35%	57.82B
ARGENX SE	-0.59%	-6.35%	+53.54%	+70.52%	53.71B
INSMED INCORPORATED	-0.27%	-5.77%	+6.75%	+433.06%	23.8B
BIONTECH SE	+1.76%	-1.65%	-16.86%	-15.01%	23.26B
WUXI BIOLOGICS (CAYMAN) INC.	-0.56%	+6.10%	+44.56%	-3.75%	20.7B
GENMAB A/S	-0.82%	-2.51%	+33.77%	-29.95%	17.81B
PHARMAESSENTIA CORPORATION	+10.00%	-4.30%	+208.33%	+370.99%	16.9B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-2.61%	+10.00%	+47.02%	+699.54%	16.36B
EXELIXIS, INC.	-0.39%	-1.00%	+26.08%	+186.49%	13.96B
Average	+2.29%	+1.89%	+52.21%	+179.45%	24.44B
Weighted average by Cap.	+1.14%	+1.35%	+51.30%	+159.18%

	2023	2024
Net sales	-	278.95 0.19 0.16 0.15 0.14 0.26 18.02 0.27 1.8 0.71 8.81 0.7 0.69 30.35
Net income	-17.88B -12M -10.49M -9.68M -8.9M -16.86M -1.15B -17.14M -116M -45.33M -564M -45.06M -44.07M -1.95B	-14.06B -9.43M -8.25M -7.61M -6.99M -13.25M -908M -13.48M -90.84M -35.64M -444M -35.43M -34.65M -1.53B
Net Debt	-45.96B -30.85M -26.97M -24.88M -22.87M -43.34M -2.97B -44.08M -297M -117M -1.45B -116M -113M -5B	-37.44B -25.13M -21.97M -20.27M -18.63M -35.3M -2.42B -35.91M -242M -94.95M -1.18B -94.38M -92.31M -4.07B